ACADIA Pharmaceuticals Sponsors National Parkinson Foundation’s Caregiver Summit

ACADIA to Host Booths and Present Posters at the 4^thWorld Parkinson Congress

SAN DIEGO—(BUSINESS WIRE)—Sep. 19, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system (CNS)disorders, is sponsoring the National Parkinson Foundation’s (NPF)Caregiver Summit that will be held today in Portland, Oregon. TheCaregiver Summit is a daylong event that brings together caregivers fromall over the world to share their experiences and everyday strategiesfor caring for someone with Parkinson’s disease. The Caregiver Summitimmediately precedes the 4^th World Parkinson Congress, whichtakes place September 20-23.

“ACADIA is proud to partner with the National Parkinson Foundation inproviding caregivers with support, education and access to much-neededresources,” said Steve Davis, ACADIA’s President and Chief ExecutiveOfficer. “Caregivers play a vital role in caring for people withParkinson’s disease – but all too often, their own needs are overlooked.The Caregiver Summit is an important step in better understanding andaddressing caregiver needs, and we are gratified to offer our support.”

“At the National Parkinson Foundation, we understand that Parkinson’sdisease has a significant impact on people who’ve gotten that diagnosis,as well as on those who care for and about them,” said Vaughn Edelson,NPF’s Director of Education. “The Caregiver Summit is an opportunity forus to offer resources and support to caregivers now and in the future,and we look forward to continued engagement with this important part ofthe Parkinson’s community.”

ACADIA at 4^th World Parkinson Congress

Following the Caregiver Summit, ACADIA will be exhibiting with twobooths at the World Parkinson Congress: Booth 700 for healthcareproviders and Booth 612, a disease education booth for consumers. Inaddition, ACADIA will present three scientific posters at the Congress:

• Decreased burden among caregivers of patients with Parkinson’s diseasepsychosis (PDP) treated with pimavanserin, a selective 5-HT_2Ainverse agonist (Poster P12.08).
• Caregivers of PDP patients have an increased risk of developingemotional and social distress that is decreased when PDP is treatedwith pimavanserin (Poster P42.11).
• The safety profile of pimavanserin: Focus on motor symptoms andextrapyramidal-related adverse events in patients with Parkinson’sdisease psychosis (PDP) (Poster P35.10).

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.

About the National Parkinson Foundation, a division of theParkinson’s Foundation

The Parkinson’s Foundation is working toward a world without Parkinson’sdisease. Formed by the merger of National Parkinson Foundation (NPF) andthe Parkinson’s Disease Foundation (PDF) in August 2016, the mission ofthe Parkinson’s Foundation is to invest in promising scientific researchthat will end Parkinson’s disease and improve the lives of people withParkinson’s, and their families, through improved treatments, supportand the best care. For more information, visit www.parkinson.orgor www.pdf.org,or call (800) 4PD-INFO (473-4636) or (800) 457-6676.

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:
ACADIA Pharmaceuticals Inc.
LisaBarthelemy, Investor Relations
(858) 558-2871
ir@acadia-pharm.com
or
MediaContact:
Taft and Partners
Ted Deutsch
(609)578-8765
ted@taftandpartners.com